Safe and Tolerable One-Hour Pamidronate Infusion for Multiple Myeloma Patients

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s4004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Comparative Effectiveness on Survival of Zoledronic Acid Versus Pamidronate in Multiple Myeloma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2014English

A 0-Hour/1-Hour Protocol for Safe, Early Discharge of Chest Pain Patients

Academic Emergency Medicine
MedicineEmergency Medicine
2017English

Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or With Dexamethasone in Relapsed and Refractory Multiple Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2010English

Myeloablative Timed Sequential Busulfan Is Safe in Patients With Relapsed or High-Risk Multiple Myeloma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Bortezomib for the Treatment of Multiple Myeloma Patients

Health Technology Assessment
MedicineHealth Policy
2009English

Treatment of Multiple Myeloma Patients Who Have Received at Least One Prior Therapy

European Oncology and Haematology
OncologyHematology
2007English

Pharmacotherapy With Pamidronate Disodium of Osteolytic Bone Metastases of Breast Cancer, Osteolytic Lesions of Multiple Myeloma, and Paget's Disease

Clinical Medicine. Therapeutics
2009English

T-Cell-Depleted Allogeneic Bone Marrow Transplantation Followed by Donor Lymphocyte Infusion in Patients With Multiple Myeloma: Induction of Graft-Versus-Myeloma Effect

Blood
BiochemistryImmunologyCell BiologyHematology
2001English

Management of Older Patients With Multiple Myeloma

Blood Reviews
OncologyHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy